Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics

The role of serotonin as the possible trigger mechanism of vomiting associated with chemotherapeutic drugs was further investigated in cancer patients (n = 86). Increases in 5-hydroxyindoleacetic acid (5-HIAA) excretion rates (2.5-2.9 times baseline values) were observed 4 to 8 hours after high-dose cisplatinum (> or = 50 mg/m2). The daily excretion of 5-HIAA from 24-48, 48-72, and 72-96 hours after cisplatinum was not different from pre-cisplatinum levels. These results, together with the efficacy data for 5-HT3 antagonists, suggests that serotonin may trigger the early, intense period of emesis, but not the period of delayed emesis, following high-dose cisplatinum. Compared with the first cycle of chemotherapy, higher peak levels and more sustained elevations of 5-HIAA excretion were found after subsequent cycles, with high-dose cisplatinum. Further, no evidence of serotonin depletion was found after a single or after repeated cycles of treatment with high-dose cisplatinum. These data suggest that the more intense emetic response associated to repeated cycles of treatment may be triggered by greater changes in serotonin release. No significant differences in the rate and amount of 5-HIAA excreted induced by low-dose (30 +/- 2 mg/m2) and high-dose (84 +/- 3 mg/m2) cisplatinum were found between those patients who received dexamethasone (D) (20 mg i.v.) and those who received metoclopramide (M) (2 mg/kg, i.v.), irrespectively of the cycle of treatment. Interestingly, for M but not for D, best antiemetic protection was observed when lower amounts of serotonin were released (i.e., low-dose cisplatinum and initial cycles of treatment).(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. I Bennett, H. J Livingstone, P. Costello, K. R Allen, and T. J Degg Symptom scores, serotonin and 5-hydroxyindole acetic acid levels in cancer patients with and without bowel obstruction Palliative Medicine, March 1, 2007; 21(2): 157 - 159. [PDF]

				G. M Higa, M. L Auber, R. Altaha, D. Piktel, S. Kurian, G. Hobbs, and K. Landreth 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy Journal of Oncology Pharmacy Practice, December 1, 2006; 12(4): 201 - 209. [Abstract] [PDF]

				C. J. Friedman, H. A. Burris III, K. Yocom, L. M. Blackburn, and D. Gruben Oral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy Oncologist, April 1, 2000; 5(2): 136 - 143. [Abstract] [Full Text]

				A. M. Castejon, X. Paez, L. Hernandez, and L. X. Cubeddu Use of Intravenous Microdialysis to Monitor Changes in Serotonin Release and Metabolism Induced by Cisplatin in Cancer Patients: Comparative Effects of Granisetron and Ondansetron J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 960 - 966. [Abstract] [Full Text]

				C P Bearcroft, D Perrett, and M J G Farthing Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study Gut, January 1, 1998; 42(1): 42 - 46. [Abstract] [Full Text] [PDF]